Details, Fiction and Z-LEHD-fmk
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review to evaluate a number of intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Key demo aims were being To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis cl